SOURCE: Vicor Technologies, Inc.

August 07, 2008 08:30 ET

Vicor Technologies to Present PD2i Vital Sign Application and Findings at the Smart Monitoring 2008 Forum

BOCA RATON, FL--(Marketwire - August 7, 2008) - David Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that Vicor will present its proprietary PD2i Vital Sign (PD2i VS) technology for risk stratifying trauma severity at the Smart Monitoring 2008 Forum on August 10, 2008 in St. Petersburg Beach, Florida. The Smart Monitoring Forum immediately precedes the Department of Defense's (DOD) 2008 Advanced Technological Assessment of Critical Combat Casualties (ATACCC) Conference.

Vicor Technologies is a medical diagnostics company that has developed the PD2i, a patented, proprietary algorithm that is now in trials for FDA 510(k) approval for use in risk stratifying a) the severity of injury and probability of survival of critically injured soldiers and civilians (PD2i Vital Sign) and b) patients who are at high or low risk of suffering sudden cardiac death (PD2i Cardiac Analyzer).

Vicor's presentation at Smart Monitoring 2008 will detail the application of its PD2i VS as an enhanced vital sign measurement to more accurately risk stratify trauma severity and the probability of survival in the critically injured. It will also provide a review of trial results conducted under a Collaborative Research and Development Agreement (CRADA) between Vicor and the U.S. Army Institute of Surgical Research (USAISR) begun in January 2008. To date, under the CRADA, Vicor has completed two studies (one human, one animal) and is in the process of completing two more studies. Vicor anticipates filing with the FDA a 510(k) application for the PD2i VS this year.

"We're extremely pleased and honored to be invited to present our technology, and recent positive trial results before this forum of prominent and influential military, medical, scientific, business, and industry professionals," stated Mr. Fater. "As Vicor moves steadily toward commercialization of its technology applications, our presence at prestigious events such as Smart Monitoring and ATACCC gain Vicor important visibility, and significantly increases our opportunity to explore new strategic relationships and collaborative efforts that enable us to identify new applications for the PD2i," Mr. Fater concluded.

Sponsored by the Resuscitation Research Laboratory of the University of Texas Medical Branch, the Smart Monitoring Forum is an open discussion focused on vital signs monitoring for combat physicians, medics, corpsmen, and nurses to discuss needs, and how current monitoring technologies meet/do not meet those needs. It also provides an opportunity for industry to present new and emerging monitoring technologies and share how their product(s) can contribute to the medical care of military and civilian trauma.

The ATACCC is the DOD's premier scientific meeting. ATACCC addresses critical advances in trauma medicine and the unique medical needs of the war fighter, with a focus on the growing and changing operational issues and identifies technologies available today and in the future that can be used to meet these increasingly complex goals.

Additional information about the Smart Monitoring 2008 Forum and ATACCC 2008 Conference may be found at http://www.utmb.edu/rrl/Announcement.html and https://www.usaccc.org/ATACCC/index.htm, respectively.

About Vicor Technologies, Inc.

Vicor Technologies, Inc. (OTCBB: VCRT) is a medical diagnostics company focused on the development of innovative diagnostics and therapeutics. Both Vicor's PD2i Vital Sign (PD2i VS) and PD2i Cardiac Analyzer employ the firm's patented, proprietary PD2i algorithm, a deterministic, non-linear analytic measure that accurately evaluates electrophysiological potentials with high sensitivity and high specificity to predict future pathological events.

The PD2i VS enables risk stratification of trauma severity to identify those in need of immediate life saving intervention and improve emergency triage efforts. The PD2i VS is currently in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research. Vicor anticipates filing with the FDA a 510(k) application for the PD2i VS this year.

The PD2i Cardiac Analyzer identifies patients at risk of suffering a fatal arrhythmic event or sudden cardiac death (SCD) within six months. The PD2i Cardiac Analyzer is currently involved in a multi-site, multi-year trial (the VITAL Trial) being conducted by the Harvard Clinical Research Institute. Vicor anticipates completion of the VITAL Trial one year following the enrollment of the last patient and FDA approval to commercialize use of the PD2i Cardiac Analyzer immediately thereafter.

Vicor anticipates developing additional applications using the PD2i algorithm to enable early detection of Alzheimer's Disease, and a variety of other disorders and diseases.

More information about Vicor Technologies may be found at www.vicortech.com.

The appearance of name-brand institutions or products in this media release does not constitute endorsement by the U.S. Army Medical Research and Materiel Command, the Department of the Army, Department of Defense or the U.S. Government of the information, products or services contained therein

Caution Regarding Forward-Looking Statements

Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ: our ability to file a 510(k) with the FDA for the PD2i VS for military and civilian applications, our ability continue to receive financing sufficient to complete the critical clinical trials for the PD2i Cardiac Analyzer; our ability to continue as a going concern; our ability to successfully develop products based on our technologies; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor's Annual Report on Form 10-KSB for the fiscal year ended December 31, 2007 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ.

Release 08-13

Contact Information